Literature DB >> 10717352

Recombinant expression and neutralizing activity of an MHC class II binding epitope of toxic shock syndrome toxin-1.

E Rubinchik1, A W Chow.   

Abstract

Toxic shock syndrome (TSS) is caused by the staphylococcal superantigen, TSST-1. The MHC class II binding domain of TSST-1 containing a conserved sequence with other related staphylococcal enterotoxins, comprising TSST-1 residues 47-64 [(T(47-64)], was expressed as a fusion protein with either glutathione-S-transferase (GST(47-64)), filamentous phage coat protein (pIII(47-64)), or E. coli outer membrane porin protein (OprF(47-64)), or synthesized as a peptide conjugated to bovine serum albumin, BSA(47-64). GST(47-64), OprF(47-64) and BSA(47-64), but not pIII(47-64), all induced high-titer T(47-64)-specific antibodies in Balb/c mice. However, only anti-GST(47-64) antibodies inhibited (125)I-TSST-1 binding to MHC class II and abrogated TSST-1-induced T cell mitogenesis and TNFalpha secretion in human peripheral blood mononuclear cells. Purified GST(47-64) also inhibited (125)I-TSST-1 binding in a dose-dependent manner. These findings suggest that GST(47-64) may have potential as a recombinant peptide vaccine or TSST-1 receptor inhibitor against TSS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10717352     DOI: 10.1016/s0264-410x(99)00554-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Engineering filamentous phage carriers to improve focusing of antibody responses against peptides.

Authors:  Nienke E van Houten; Kevin A Henry; George P Smith; Jamie K Scott
Journal:  Vaccine       Date:  2010-01-05       Impact factor: 3.641

2.  Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide.

Authors:  N E van Houten; M B Zwick; A Menendez; J K Scott
Journal:  Vaccine       Date:  2006-01-11       Impact factor: 3.641

Review 3.  Beyond phage display: non-traditional applications of the filamentous bacteriophage as a vaccine carrier, therapeutic biologic, and bioconjugation scaffold.

Authors:  Kevin A Henry; Mehdi Arbabi-Ghahroudi; Jamie K Scott
Journal:  Front Microbiol       Date:  2015-08-04       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.